Chembio diagnostics awarded $12.7 million by barda for development of rapid dpp respiratory antigen panel and 510(k) submission of the rapid dpp sars-cov-2 antigen test system

Hauppauge, n.y., dec. 02, 2020 (globe newswire) -- chembio diagnostics, inc. (nasdaq: cemi) a leading point-of-care diagnostic company focused on infectious diseases, today announced it has been awarded a contract from the biomedical advanced research and development authority (barda), which is part of the u.s. department of health and human services' office of the assistant secretary for preparedness and response. the contract will support the development and pursuit of u.s. food and drug administration (fda) emergency use authorization (eua) for a rapid, multiplex dpp respiratory antigen panel point-of-care test system using chembio's proprietary dpp technology for the upcoming flu season.
CEMI Ratings Summary
CEMI Quant Ranking